TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Depression Following Bypass Surgery
Brief Summary: The purpose of this study is to treat depression in patients who have undergone coronary artery bypass graft (CABG).


Options:
A: Arm Label: Cardio fit; Type: EXPERIMENTAL; Interventions: Behavioral: CardioFit | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CardioFit; Assigned to Arm(s): Cardio fit
B: Arm Label: Quality improvement program; Type: OTHER; Interventions: Other: multifaceted strategy | Arm Label: Hospital standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: multifaceted strategy; Assigned to Arm(s): Quality improvement program
C: Arm Label: Enhanced Internet-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored content, Behavioral: Generic Internet-based information, Behavioral: Discussion forum, Behavioral: Behavioral monitoring | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Generic Internet-based information, Behavioral: Discussion forum | Intervention Type: BEHAVIORAL; Name: Tailored content; Assigned to Arm(s): Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Generic Internet-based information; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Discussion forum; Assigned to Arm(s): Control, Enhanced Internet-based intervention | Intervention Type: BEHAVIORAL; Name: Behavioral monitoring; Assigned to Arm(s): Enhanced Internet-based intervention
D: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Depression Following Bypass Surgery
Brief Summary: The purpose of this study is to treat depression in patients who have undergone coronary artery bypass graft (CABG).


Options:
A: Arm Label: REP + EF; Type: EXPERIMENTAL; Interventions: Behavioral: External Facilitation | Arm Label: REP + EF/IF; Type: EXPERIMENTAL; Interventions: Behavioral: External + Internal Facilitation | Intervention Type: BEHAVIORAL; Name: External Facilitation; Assigned to Arm(s): REP + EF | Intervention Type: BEHAVIORAL; Name: External + Internal Facilitation; Assigned to Arm(s): REP + EF/IF
B: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care
C: Arm Label: Implementation Facilitation; Type: EXPERIMENTAL; Interventions: Other: Replicating Effective Programs plus External Facilitation | Arm Label: Educational Materials; Type: PLACEBO_COMPARATOR; Interventions: Other: Educational Materials | Intervention Type: OTHER; Name: Replicating Effective Programs plus External Facilitation; Assigned to Arm(s): Implementation Facilitation | Intervention Type: OTHER; Name: Educational Materials; Assigned to Arm(s): Educational Materials
D: Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: Nurse-led case management | Intervention Type: BEHAVIORAL; Name: Nurse-led case management; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Depression Following Bypass Surgery
Brief Summary: The purpose of this study is to treat depression in patients who have undergone coronary artery bypass graft (CABG).


Options:
A: Arm Label: Internet-based CBT; Type: EXPERIMENTAL; Interventions: Behavioral: Internet-based CBT | Arm Label: Treatment as usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Internet-based CBT; Assigned to Arm(s): Internet-based CBT
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI) | Intervention Type: OTHER; Name: Transtheoretical model-based (TTM - based) intervention and motivational interviewing (MI); Assigned to Arm(s): Intervention group
C: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care
D: Arm Label: ACT-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACT-based intervention, Behavioral: usual care | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: usual care | Intervention Type: BEHAVIORAL; Name: ACT-based intervention; Assigned to Arm(s): ACT-based intervention | Intervention Type: BEHAVIORAL; Name: usual care; Assigned to Arm(s): ACT-based intervention, Usual care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Program to Reduce Incontinence by Diet and Exercise
Brief Summary: PRIDE will evaluate the impact of weight loss on urinary incontinence in a randomized, controlled trial.


Options:
A: Intervention Type: BEHAVIORAL; Name: Exercise and diet - based on DPS and DPP; Assigned to Arm(s): N/A
B: Arm Label: Group 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Modification | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Group 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Behavioral: Lifestyle Modification | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Group 3, Group 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1, Group 2 | Intervention Type: BEHAVIORAL; Name: Lifestyle Modification; Assigned to Arm(s): Group 2, Group 4
C: Arm Label: Lifestyle & Behavioral Change Program; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle & Behavioral Change Program | Arm Label: Structured Education Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Education Program | Intervention Type: BEHAVIORAL; Name: Lifestyle & Behavioral Change Program; Assigned to Arm(s): Lifestyle & Behavioral Change Program | Intervention Type: BEHAVIORAL; Name: Structured Education Program; Assigned to Arm(s): Structured Education Program
D: Intervention Type: BEHAVIORAL; Name: Paleolithic diet; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Program to Reduce Incontinence by Diet and Exercise
Brief Summary: PRIDE will evaluate the impact of weight loss on urinary incontinence in a randomized, controlled trial.


Options:
A: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: group of pelvic floor exercises; Type: EXPERIMENTAL; Interventions: Procedure: group of pelvic floor exercises | Arm Label: anal electrostimulation group; Type: EXPERIMENTAL; Interventions: Procedure: group of pelvic floor exercises, Procedure: anal electrostimulation group | Intervention Type: PROCEDURE; Name: group of pelvic floor exercises; Assigned to Arm(s): anal electrostimulation group, group of pelvic floor exercises | Intervention Type: PROCEDURE; Name: anal electrostimulation group; Assigned to Arm(s): anal electrostimulation group
B: Arm Label: Transcutaneous perineal stimulation; Type: EXPERIMENTAL; Interventions: Other: Transcutaneous perineal stimulation | Arm Label: Anal stimulation; Type: ACTIVE_COMPARATOR; Interventions: Other: Anal stimulation | Intervention Type: OTHER; Name: Transcutaneous perineal stimulation; Assigned to Arm(s): Transcutaneous perineal stimulation | Intervention Type: OTHER; Name: Anal stimulation; Assigned to Arm(s): Anal stimulation
C: Arm Label: Kegel exercise education; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Extracorporeal biofeedback device; Type: EXPERIMENTAL; Interventions: Device: Extracorporeal biofeedback device (Any Kegel) | Intervention Type: DEVICE; Name: Extracorporeal biofeedback device (Any Kegel); Assigned to Arm(s): Extracorporeal biofeedback device
D: Arm Label: Lifestyle & Behavioral Change Program; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle & Behavioral Change Program | Arm Label: Structured Education Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Education Program | Intervention Type: BEHAVIORAL; Name: Lifestyle & Behavioral Change Program; Assigned to Arm(s): Lifestyle & Behavioral Change Program | Intervention Type: BEHAVIORAL; Name: Structured Education Program; Assigned to Arm(s): Structured Education Program

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Program to Reduce Incontinence by Diet and Exercise
Brief Summary: PRIDE will evaluate the impact of weight loss on urinary incontinence in a randomized, controlled trial.


Options:
A: Arm Label: bladdertraining group; Type: EXPERIMENTAL; Interventions: Behavioral: bladdertraining in groups | Arm Label: bladdertraining individually; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: bladdertraining individually | Intervention Type: BEHAVIORAL; Name: bladdertraining in groups; Assigned to Arm(s): bladdertraining group | Intervention Type: BEHAVIORAL; Name: bladdertraining individually; Assigned to Arm(s): bladdertraining individually
B: Arm Label: Lifestyle & Behavioral Change Program; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle & Behavioral Change Program | Arm Label: Structured Education Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Education Program | Intervention Type: BEHAVIORAL; Name: Lifestyle & Behavioral Change Program; Assigned to Arm(s): Lifestyle & Behavioral Change Program | Intervention Type: BEHAVIORAL; Name: Structured Education Program; Assigned to Arm(s): Structured Education Program
C: Arm Label: Combination therapy; Type: EXPERIMENTAL; Interventions: Drug: Tolterodine, Behavioral: Behavioral training | Arm Label: Drug therapy alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine | Intervention Type: DRUG; Name: Tolterodine; Assigned to Arm(s): Combination therapy, Drug therapy alone | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Combination therapy
D: Arm Label: Group 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training and leaflet | Arm Label: Group 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured training | Arm Label: Group 3; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Leaflet | Arm Label: Group 4; Type: SHAM_COMPARATOR; Interventions: Behavioral: Control Group | Intervention Type: BEHAVIORAL; Name: Structured training and leaflet; Assigned to Arm(s): Group 1 | Intervention Type: BEHAVIORAL; Name: Structured training; Assigned to Arm(s): Group 2 | Intervention Type: BEHAVIORAL; Name: Leaflet; Assigned to Arm(s): Group 3 | Intervention Type: BEHAVIORAL; Name: Control Group; Assigned to Arm(s): Group 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Program to Reduce Incontinence by Diet and Exercise
Brief Summary: PRIDE will evaluate the impact of weight loss on urinary incontinence in a randomized, controlled trial.


Options:
A: Arm Label: Yoga Therapy; Type: EXPERIMENTAL; Interventions: Other: Yoga Therapy Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Yoga Therapy Program; Assigned to Arm(s): Yoga Therapy
B: Arm Label: Lifestyle & Behavioral Change Program; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle & Behavioral Change Program | Arm Label: Structured Education Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Education Program | Intervention Type: BEHAVIORAL; Name: Lifestyle & Behavioral Change Program; Assigned to Arm(s): Lifestyle & Behavioral Change Program | Intervention Type: BEHAVIORAL; Name: Structured Education Program; Assigned to Arm(s): Structured Education Program
C: Arm Label: Exercise training; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise training
D: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Once Weekly Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis
Brief Summary: This study is to evaluate and compare the effects of Alendronate and Risedronate to treat women with postmenopausal osteoporosis. The primary hypothesis for this study is that in postmenopausal women with osteoporosis, treatment with oral alendronate 70 mg once weekly will produce a mean percent increase from baseline in hip trochanter bone mineral density (BMD) at 12 and 24 months which is greater than that observed with oral risedronate 35 mg once weekly.


Options:
A: Intervention Type: DRUG; Name: MK0217, alendronate sodium/Duration of Intervention: 12 mo; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: risedronate / Duration of Intervention: 12 mo; Assigned to Arm(s): N/A
B: Arm Label: Genistein vs. Risedronate; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Genistein vs Risedronate | Arm Label: Genistein dose and source; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Genistein vs Risedronate | Intervention Type: DIETARY_SUPPLEMENT; Name: Genistein vs Risedronate; Assigned to Arm(s): Genistein dose and source, Genistein vs. Risedronate
C: Arm Label: Teriparatide; Type: EXPERIMENTAL; Interventions: Drug: Teriparatide, Drug: Placebo, Drug: Calcium, Drug: Vitamin D | Arm Label: Risedronate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risedronate, Drug: Placebo, Drug: Calcium, Drug: Vitamin D | Intervention Type: DRUG; Name: Teriparatide; Assigned to Arm(s): Teriparatide | Intervention Type: DRUG; Name: Risedronate; Assigned to Arm(s): Risedronate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Risedronate, Teriparatide | Intervention Type: DRUG; Name: Calcium; Assigned to Arm(s): Risedronate, Teriparatide | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): Risedronate, Teriparatide
D: Arm Label: Alendronate 70 mg; Type: EXPERIMENTAL; Interventions: Drug: Alendronate, Dietary Supplement: Elemental Calcium, Dietary Supplement: Vitamin D, Drug: Risendronate placebo | Arm Label: Risendronate 35 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risedronate 35 mg, Dietary Supplement: Elemental Calcium, Dietary Supplement: Vitamin D, Drug: Alendronate placebo | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): Alendronate 70 mg | Intervention Type: DRUG; Name: Risedronate 35 mg; Assigned to Arm(s): Risendronate 35 mg | Intervention Type: DIETARY_SUPPLEMENT; Name: Elemental Calcium; Assigned to Arm(s): Alendronate 70 mg, Risendronate 35 mg | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Alendronate 70 mg, Risendronate 35 mg | Intervention Type: DRUG; Name: Risendronate placebo; Assigned to Arm(s): Alendronate 70 mg | Intervention Type: DRUG; Name: Alendronate placebo; Assigned to Arm(s): Risendronate 35 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis; A 12 Month Extension to: A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to Evaluate and Compare the Effects of Alendronate and Risedronate on Bone Mineral Density in Postmenopausal Women With Osteoporosis
Brief Summary: The purpose of this study and 12 month extension is to evaluate the effects of two investigational drugs on osteoporosis in postmenopausal women.


Options:
A: Arm Label: Teriparatide; Type: EXPERIMENTAL; Interventions: Drug: Teriparatide, Drug: Placebo, Drug: Calcium, Drug: Vitamin D | Arm Label: Risedronate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risedronate, Drug: Placebo, Drug: Calcium, Drug: Vitamin D | Intervention Type: DRUG; Name: Teriparatide; Assigned to Arm(s): Teriparatide | Intervention Type: DRUG; Name: Risedronate; Assigned to Arm(s): Risedronate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Risedronate, Teriparatide | Intervention Type: DRUG; Name: Calcium; Assigned to Arm(s): Risedronate, Teriparatide | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): Risedronate, Teriparatide
B: Intervention Type: DRUG; Name: MK0217, alendronate sodium/Duration of Intervention: 12 mo; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: risedronate / Duration of Intervention: 12 mo; Assigned to Arm(s): N/A
C: Arm Label: 5 mg Before Breakfast; Type: ACTIVE_COMPARATOR; Interventions: Drug: risedronate | Arm Label: 35 mg After Breakfast; Type: EXPERIMENTAL; Interventions: Drug: risedronate | Arm Label: 35 mg Before Breakfast; Type: EXPERIMENTAL; Interventions: Drug: risedronate | Intervention Type: DRUG; Name: risedronate; Assigned to Arm(s): 5 mg Before Breakfast | Intervention Type: DRUG; Name: risedronate; Assigned to Arm(s): 35 mg After Breakfast | Intervention Type: DRUG; Name: risedronate; Assigned to Arm(s): 35 mg Before Breakfast
D: Arm Label: Alendronate 70 mg; Type: EXPERIMENTAL; Interventions: Drug: Alendronate, Dietary Supplement: Elemental Calcium, Dietary Supplement: Vitamin D, Drug: Risendronate placebo | Arm Label: Risendronate 35 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risedronate 35 mg, Dietary Supplement: Elemental Calcium, Dietary Supplement: Vitamin D, Drug: Alendronate placebo | Intervention Type: DRUG; Name: Alendronate; Assigned to Arm(s): Alendronate 70 mg | Intervention Type: DRUG; Name: Risedronate 35 mg; Assigned to Arm(s): Risendronate 35 mg | Intervention Type: DIETARY_SUPPLEMENT; Name: Elemental Calcium; Assigned to Arm(s): Alendronate 70 mg, Risendronate 35 mg | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Alendronate 70 mg, Risendronate 35 mg | Intervention Type: DRUG; Name: Risendronate placebo; Assigned to Arm(s): Alendronate 70 mg | Intervention Type: DRUG; Name: Alendronate placebo; Assigned to Arm(s): Risendronate 35 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety of Gardasil (V501) Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Consistency Lots for 16- to 23-Year-Old Women With and Additional Immunogenicity Bridge to the Monovalent HPV 16 Vaccine Pilot Manufacturing Lot Study-The F.U.T.U.R.E. Study (Females United to Unilaterally Reduce Endo/Ectocervical Disease)
Brief Summary: The purpose of the study is to determine if an investigational vaccine with a single component develops an immune response that is similar to the equivalent investigational vaccine with four components to reduce cervical disease.


Options:
A: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Biological: Cervarix vaccine | Arm Label: Engerix-B Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Engerix-B vaccine | Intervention Type: BIOLOGICAL; Name: Cervarix vaccine; Assigned to Arm(s): Cervarix Group | Intervention Type: BIOLOGICAL; Name: Engerix-B vaccine; Assigned to Arm(s): Engerix-B Group
B: Arm Label: Cervarix Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling, Procedure: Collection of cervical specimen, Biological: Cervarix | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Blood sampling, Procedure: Collection of cervical specimen | Intervention Type: PROCEDURE; Name: Blood sampling; Assigned to Arm(s): Cervarix Group, Placebo Group | Intervention Type: PROCEDURE; Name: Collection of cervical specimen; Assigned to Arm(s): Cervarix Group, Placebo Group | Intervention Type: BIOLOGICAL; Name: Cervarix; Assigned to Arm(s): Cervarix Group
C: Intervention Type: BIOLOGICAL; Name: V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: V501 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Comparator: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Biological: Human Papillomavirus (HPV) 16 Monovalent | Intervention Type: BIOLOGICAL; Name: V501; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Comparator: Placebo; Assigned to Arm(s): 2 | Intervention Type: BIOLOGICAL; Name: Human Papillomavirus (HPV) 16 Monovalent; Assigned to Arm(s): 3

Answer: C